Prelude Therapeutics (PRLD)
(Real Time Quote from BATS)
$2.43 USD
-0.17 (-6.54%)
Updated Sep 17, 2024 02:38 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Prelude Therapeutics Incorporated [PRLD]
Reports for Purchase
Showing records 1 - 16 ( 16 total )
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
2Q24 Financials; SMARCA2 Data Expected at ESMO; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
Investors Focusing On Initial PRT3789 Results; 2023 Financials; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
Pipeline Pared; AbCellera Partnership; 3Q23 Financials; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
Triple Meeting Takeaways; Reducing PT to $6 on PRT2527 Solid Tumor Outlook
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
Numerous Data Updates Upcoming; 2Q23 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
2022 Financials; PRT2527 + Zanubrutinib to be Tested; Raising PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
Several Datasets Expected in 2023; 3Q22 Financials Reported; Modulating PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
SMARCA2 Degrader Cleared to Enter Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
PRT2527 Slated to Enter Clinic by Year End; 3Q21 Financials; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
Too Early to Judge PRT543 and PRT811 Efficacy, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
All Eyes on the Triple Meeting; 2Q21 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
Company: Prelude Therapeutics Incorporated
Industry: Medical - Drugs
Pushing the Periphery of Precision Medicine; Initiating at Buy and $62 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
|